Baker Bros. Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-751,927
| Closed | -$72.9M | – | 114 |
|
|
2019
Q3 | $72.9M | Hold |
751,927
| – | – | 0.5% | 18 |
|
|
2019
Q2 | $77M | Hold |
751,927
| – | – | 0.52% | 19 |
|
|
2019
Q1 | $85.6M | Sell |
751,927
-632,203
| -46% | -$46.5M | 0.55% | 19 |
|
|
2018
Q4 | $54.2M | Hold |
1,384,130
| – | – | 0.44% | 21 |
|
|
2018
Q3 | $75.5M | Hold |
1,384,130
| – | – | 0.5% | 23 |
|
|
2018
Q2 | $115M | Hold |
1,384,130
| – | – | 0.86% | 12 |
|
|
2018
Q1 | $92.2M | Hold |
1,384,130
| – | – | 0.78% | 16 |
|
|
2017
Q4 | $71.2M | Hold |
1,384,130
| – | – | 0.62% | 17 |
|
|
2017
Q3 | $123M | Buy |
1,384,130
+65,789
| +5% | +$5M | 1% | 11 |
|
|
2017
Q2 | $78.8M | Hold |
1,318,341
| – | – | 0.69% | 13 |
|
|
2017
Q1 | $70.3M | Hold |
1,318,341
| – | – | 0.58% | 16 |
|
|
2016
Q4 | $65.8M | Hold |
1,318,341
| – | – | 0.64% | 17 |
|
|
2016
Q3 | $79.2M | Hold |
1,318,341
| – | – | 0.72% | 15 |
|
|
2016
Q2 | $67.4M | Buy |
1,318,341
+55,959
| +4% | +$2.39M | 0.71% | 15 |
|
|
2016
Q1 | $37.3M | Hold |
1,262,382
| – | – | 0.39% | 28 |
|
|
2015
Q4 | $57.2M | Hold |
1,262,382
| – | – | 0.47% | 26 |
|
|
2015
Q3 | $52.7M | Hold |
1,262,382
| – | – | 0.49% | 23 |
|
|
2015
Q2 | $76.1M | Sell |
1,262,382
-65,069
| -5% | -$4.3M | 0.67% | 20 |
|
|
2015
Q1 | $103M | Buy |
+1,327,451
| New | +$76.4M | 0.86% | 15 |
|
Baker Bros. Advisors's ONCE Position: Q4 2019 in Review
Baker Bros. Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 751,927 shares — an estimated $72.9M sold.
Baker Bros. Advisors first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $123M in Q3 2017. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Baker Bros. Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Baker Bros. Advisors sold 751,927 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $72.9M.
- Baker Bros. Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- Baker Bros. Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $123M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.